Ad
related to: list of approved complement inhibitors
Search results
Results from the WOW.Com Content Network
C1-inhibitor (C1-inh, C1 esterase inhibitor) is a protease inhibitor belonging to the serpin superfamily. [5] Its main function is the inhibition of the complement system to prevent spontaneous activation but also as the major regulator of the contact system.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. [13] It binds to the complement C5 protein and inhibits activation of the complement system, a part of the body's immune system. [16]
Avacincaptad pegol is a complement inhibitor. [1] Avacincaptad pegol was approved for medical use in the United States in August 2023. [2] [3] [4] Medical uses.
Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5). [8] [7]
Zilucoplan is a cyclic peptide that binds to the protein complement component 5 (C5) and inhibits its cleavage into C5a and C5b. [ 11 ] Zilucoplan was approved for medical use in the United States in October 2023, [ 6 ] [ 12 ] in the European Union in December 2023, [ 7 ] and in Australia in July 2024.
It is a complement factor B inhibitor that was developed by Novartis. [4] It is taken by mouth. [4] Iptacopan was approved by the US Food and Drug Administration (FDA) for the treatment of adults with paroxysmal nocturnal hemoglobinuria in December 2023. [6] [7] The FDA considers it to be a first-in-class medication. [8]
Pegcetacoplan acts as a complement inhibitor, specifically targeting complement protein C3, which plays a crucial role in the pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH). In individuals with PNH, there is a heightened and uninhibited complement activity, which may lead to intravascular (inside blood vessels) or extravascular ...
Ad
related to: list of approved complement inhibitors